53 reports of this reaction
8.8% of all FAMOTIDINE, CALCIUM CARBONATE AND MAGNESIUM HYDROXIDE reports
#2 most reported adverse reaction
CHRONIC KIDNEY DISEASE is the #2 most commonly reported adverse reaction for FAMOTIDINE, CALCIUM CARBONATE AND MAGNESIUM HYDROXIDE, manufactured by HyVee Inc. There are 53 FDA adverse event reports linking FAMOTIDINE, CALCIUM CARBONATE AND MAGNESIUM HYDROXIDE to CHRONIC KIDNEY DISEASE. This represents approximately 8.8% of all 604 adverse event reports for this drug.
Patients taking FAMOTIDINE, CALCIUM CARBONATE AND MAGNESIUM HYDROXIDE who experience chronic kidney disease should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CHRONIC KIDNEY DISEASE is moderately reported among FAMOTIDINE, CALCIUM CARBONATE AND MAGNESIUM HYDROXIDE users, representing a notable but not dominant share of adverse events.
In addition to chronic kidney disease, the following adverse reactions have been reported for FAMOTIDINE, CALCIUM CARBONATE AND MAGNESIUM HYDROXIDE:
The following drugs have also been linked to chronic kidney disease in FDA adverse event reports:
CHRONIC KIDNEY DISEASE has been reported as an adverse event in 53 FDA reports for FAMOTIDINE, CALCIUM CARBONATE AND MAGNESIUM HYDROXIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
CHRONIC KIDNEY DISEASE accounts for approximately 8.8% of all adverse event reports for FAMOTIDINE, CALCIUM CARBONATE AND MAGNESIUM HYDROXIDE, making it one of the most commonly reported side effect.
If you experience chronic kidney disease while taking FAMOTIDINE, CALCIUM CARBONATE AND MAGNESIUM HYDROXIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.